Results 101 to 110 of about 2,258,994 (317)

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma

open access: yesNature Communications
NK cells are critical mediators of anti-tumor immunity whose function is frequently compromised in the tumor microenvironment. Here we identify SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) as a previously unrecognized immune ...
Ruifeng Wang   +10 more
doaj   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov   +3 more
wiley   +1 more source

Metabolites beyond metabolism: Exploring their atypical roles in protein modification and signaling transduction

open access: yesChinese Medical Journal
. This comprehensive review explores the atypical metabolic roles of metabolites, extending beyond their conventional functions in energy production and biosynthesis.
Wenjuan Yang   +3 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Immune Cell Responses to the Cattle Lungworm, Dictyocaulus viviparus [PDF]

open access: yes, 2008
The cattle lungworm, Dictyocaulus viviparus, is a parasitic nematode, which can cause severe pulmonary disease. Repeated natural infections result in protective immunity, and a live attenuated vaccine exists.
Hagberg, Malin
core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Anti-tumor immune response in glioblastoma induced by 5-ALA-based PDT? (Invited Paper)

open access: yes, 2016
Longtime survivals have been observed after 5-ALA-based PDT of glioblastoma patients. This may partly be attributed to immune response stimulation. Oligonucleotide microarray analyses after sub-lethal in vitro PDT revealed upregulation of chemokine genes,
Mueller, P.   +7 more
core  

Artificial Immune Systems: A Novel Approach to Pattern Recognition [PDF]

open access: yes, 2002
This chapter introduces a new computational intelligence paradigm to perform pattern recognition, named Artificial Immune Systems (AIS). AIS take inspiration from the immune system in order to build novel computational tools to solve problems in a vast ...
Timmis, Jon, de Castro, Leandro N.
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy